Games developer tinyBuild seeks to boost £500 million market cap by becoming a media company. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE
Games developer tinyBuild seeks to boost £500 million market cap by becoming a media company
Games developer tinyBuild seeks to boost £500 million market cap by becoming a media companyView Video
Samarkand Group update the market at the London South East Aquis Special webinar
Samarkand Group update the market at the London South East Aquis Special webinarView Video

Latest Share Chat

TOP NEWS: Glaxo Partners With Sanofi To Develop Covid-19 Vaccine

Tue, 14th Apr 2020 12:20

(Alliance News) - GlaxoSmithKline PLC said Tuesday it has signed a letter of intent with French pharmaceutical firm Sanofi SA to collaborate on the development of an adjuvanted vaccine for Covid-19.

Under the partnership, Glaxo will provide its pandemic adjuvant technology, which can be used in a pandemic situation to reduce the amount of vaccine protein required per dose, allowing more doses to be produced.

Sanofi meanwhile will put forward its S-protein Covid-19 antigen, based on recombinant DNA technology. This has produced an exact genetic match to proteins found on the surface of the virus.

Both firms plan to start phase one clinical trials in the second half of 2020, and if successful, will look to complete development required for availability by the second half of 2021.

Both companies have entered a material transfer agreement allowing them to work together immediately, while definitive terms of the collaboration are set to be finalised over the next few weeks.

"This collaboration brings two of the world's largest vaccines companies together. By combining our science and our technologies, we believe we can help accelerate the global effort to develop a vaccine to protect as many people as possible from Covid-19," said Glaxo Chief Executive Officer Emma Walmsley.

Shares in GlaxoSmithKline were up 1.8% at 1,572.20 pence on Tuesday in London, while Sanofi shares in Paris were 2.6% higher at EUR84.16.

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

Related Shares

More News

IP Group investee Apollo Therapeutics completes USD145 million raise

IP Group investee Apollo Therapeutics completes USD145 million raise

17 Jun 21 09:48

BROKER RATINGS: Bank of America double upgrades Morrisons to Buy

BROKER RATINGS: Bank of America double upgrades Morrisons to Buy

17 Jun 21 09:36

Wednesday broker round-up

(Sharecast News) - Pets At Home: Berenberg reiterates buy with a target price of 540p.

16 Jun 21 12:50

Tuesday broker round-up

(Sharecast News) - Page Group: Morgan Stanley downgrades to underweight with a target price of 545p.

15 Jun 21 13:39

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.